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Abstract 
 
Background:  
Prostacyclin mimetics are vasodilatory agents used in the treatment of pulmonary arterial 
hypertension. The direct effects of prostanoids on right ventricular (RV) function are unknown. 
We aimed to investigate the direct effects of prostacyclin mimetics on RV function in hearts with 
and without RV hypertrophy and failure.  
 
Methods:  
Wistar rats were subjected to pulmonary trunk banding to induce compensated RV hypertrophy 
(n=32) or manifest RV failure (n=32). Rats without banding served as healthy controls (n=30). 
The hearts were excised and perfused in a Langendorff system and subjected to iloprost, 
treprostinil, epoprostenol or MRE-269 in increasing concentrations. The effect on RV function 
was evaluated using a balloon-tipped catheter inserted into the RV.  
 
Results: 
In control hearts iloprost, treprostinil and MRE-269, improved RV function. The effect was, 
however, absent in hearts with RV hypertrophy and failure. Treprostinil and MRE-269 even 
impaired RV function in hearts with manifest RV failure. 
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Conclusion:  
Iloprost, treprostinil and MRE-269 improved RV function in the healthy rat heart. RV hypertrophy 
abolished the positive inotropic effect and in the failing right ventricle, MRE-269 and treprostinil 
impaired RV function. This may be related to changes in prostanoid receptor expression and 
reduced coronary flow reserve in the hypertrophic and failing right ventricle. 
 
Key words: prostacyclin, contractility, right ventricular failure, prostanoid receptors, pulmonary 
arterial hypertension 
 
 
1 Introduction 
 
Prostacyclins have since the 80’s been a cornerstone in the treatment of pulmonary arterial 
hypertension (PAH) owing to effective vasodilatory, antiproliferative and anti-thrombotic 
properties.1-3 Despite optimal drug therapy, PAH remains a devastating disease leading to impaired 
quality of life and premature death.4 Although PAH originates in the pulmonary vasculature, 
prognosis is closely associated with progression of right ventricular (RV) dysfunction and failure. 
The right ventricle suffers from sustained pressure overload, leading to hypertrophy, fibrosis and 
ultimately dilatation and failure, leaving RV failure the most common cause of death in patients 
with PAH.5,6  
The inotropic effects of prostacyclin analogues in the right ventricle have only been investigated in 
a few previous studies.7-11 Kemming and collegues reported increased RV contractility in healthy 
pigs when subjected to epoprostenol and iloprost inhalation11 while others have investigated them 
in several different models for RV failure.7,9,10,12 However, models with unfixed afterload make it 
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difficult to separate direct effects on the heart from those resulting in changes in the systemic and 
pulmonary circulation.  
 
While prostacyclins are potent activators of the IP receptor, they will to varying degrees activate 
other prostanoid receptors.13 This prompted the development of the IP receptor specific drug, 
selexipag.14 The eight G-protein coupled prostanoid receptor subtypes work through different 
subcellular pathways (Gs, Gi, Gq). They are divided into subfamilies based on their ability to relax 
or contract smooth muscle.13,15 The prostacyclin analogues, used in the treatment of PAH, have 
diverse affinity and selectivity for the receptor subtypes.16,17 The distribution and function of these 
different receptor subtypes in the pulmonary vasculature have been investigated in recent 
years.16,18,19 The distribution in the right ventricle and its influence on the effect of the 
prostacyclins on the right heart remains, however, to be characterized.  
In the present study we investigated the direct effects of iloprost, treprostinil, epoprostenol and 
MRE-269, the metabolite from selexipag, on RV function in the normal right ventricle and in a 
model of pressure overload-induced RV hypertrophy and failure. Choosing the isolated perfused 
heart model not only allowed us to test a wide dose range, but also excluded potential influence 
from the pulmonary and systemic circulation. We also investigated the role of the different 
prostanoid receptors in the right ventricle to help further characterize the myocardial action of 
prostacyclin mimetics. 
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Methods 
 
Outbred, male, Wistar rats were used in the experiments (n=149). The rats were housed in pairs, 
allowed free access to water and standard rat chow and subjected to a 12-hour light-dark cycle. All 
experiments were performed in concordance with the Guide for the Care and Use of Laboratory 
Animals (NIH, 2011)20 and were approved by the Danish Animal Experiments Inspectorate 
(Authorization number: 2012-15-2934-00384). Method details are provided in the supplementary 
material online. 
 
Rat model of RV hypertrophy and failure 
Anesthesia was induced with 7% sevofluran and maintained with 3.5% sevoflurane in a mixture of 
O2 1 L/min and N2O 0.5 L/min. To reduce post-operative pain, buprenorphine was injected 
subcutaneously (0.12 mg/kg) during the procedure and applied to the drinking water (7.4 µg/mL) 
for three days postoperatively. 
RV hypertrophy and failure were induced by pulmonary trunk banding (PTB) as previously 
described.8,21 The banding clip was applied in rats (90±5 g) and compressed to an inner diameter 
of 1.0 mm (n=32) or 0.5 mm (n=32). The rats were left for 7 weeks generating either RV 
hypertrophy (HYP) or manifest RV failure (FAIL). Rats without banding served as healthy 
controls (CON).  
 
Echocardiography 
Before isolating the hearts, RV hypertrophy and function were evaluated using a Vevo 2100 
echocardiographic system (Visual Sonics, Toronto, Canada) with a 21 MHz linear array 
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transducer. All analyses were made during expiration and are presented as the mean of three 
consecutive measurements.  
 
The isolated perfused heart model - Langendorff 
Anaesthesia was induced with a subcutaneous injection of a mix of midazolam, fentanyl citrate 
and fluanisone. The aorta was cannulated and retrograde perfusion was initiated before cutting out 
the heart. It was connected to a pressure-controlled Langendorff system as previously described.22 
Krebs-Henseleit buffer was used as perfusion media, gassed with 95% O2 and 5% CO2 to keep the 
pH at 7.4 and the heart oxygenated. 
RV hemodynamic parameters were monitored using a fluid-filled balloon introduced into the right 
ventricle and connected to a pressure transducer.  
Coronary flow rate was measured using an in-line flow probe as an integrated part of the modified 
Langendorff setup (Type 2.5SB, Transonic System Inc. Ithaca, NY, USA). Coronary flow reserve 
(CFR) was estimated as CFR = CFmax/CFbaseline after coronary flow was normalized to the weight 
of the heart. CFmax: the maximum flow reached with prostacyclin mimetic administration was used 
as CFmax. CFbaseline: coronary flow at baseline. 
 
Study design 
 
Effects of prostacyclins on RV function 
Control (n=30), hypertrophic (n=32) and failing hearts (n=32) were mounted in the Langendorff 
system and after 20-30 min of stabilization, each heart was perfused with iloprost (0.02-6 ng/mL), 
treprostinil (0.5-150 ng/mL), epoprostenol (0.06-20 ng/mL) or MRE-269 (30-10000 ng/mL). The 
hearts were perfused with each concentration for 10 min followed by 5 min perfusion of 
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dobutamine (0.1 µg/mL) to test the contractile reserve of each isolated heart. Iloprost, treprostinil, 
epoprostenol and selexipag are all clinically available agents used in the treatment of pulmonary 
arterial hypertension. MRE-269, the active metabolite of selexipag, is approved only for 
experimental use.  
 
Coronary artery dilatation and RV function 
A potential association between coronary artery dilatation and RV function was investigated in 
additional two sets of experiments. One set of healthy hearts (n=7) was subjected to treprostinil 
perfusion as described above, while keeping the flow constant at 13 mL/min throughout the 
experiment. As the hearts were perfused with increasing concentrations of treprostinil, causing a 
gradual coronary vasodilation, the perfusion pressure was manually decreased keeping the 
coronary flow at 13 mL/min. At the end of the protocol the hearts were perfused with a dose of 
dobutamine to verify the ability to induce an inotropic response despite a constant coronary flow 
and a decreasing perfusion pressure.  
Another set of healthy (n=8), hypertrophic (n=8) and failing (n=8) rat hearts were perfused with 
the vasodilator, sodium nitroprusside (Nitropress®, Hospira, Inc., Lake Forest, USA) (0.125-0.5 
µg/mL), to investigate the effect of coronary vasodilation by a pure vasodilator on RV function. 
 
Expression of prostanoid receptors in the right ventricle 
RV tissue excised from healthy hearts (n=8), hearts with RV hypertrophy (n=8) and hearts with 
RV failure (n=8) was snapped frozen in liquid nitrogen and cDNA was synthesized from RNA 
isolated from the RV tissue. Primers used in quantitative polymerase chain reaction (qPCR) were 
designed for the β-myosin heavy chain (β-MHC), sarco/endoplasmatic reticulum Ca2+-ATPase 2 
(SERCA-2) and the rat prostanoid receptors IP, EP1, EP2, EP3, EP4, DP1, TP and FP genes (Table 
Copyright  2016 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
AC
CE
PT
ED
 8 
s1, supplementary material). The level of mRNA was normalized to the reference gene, 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH). 
 
 
Prostanoid receptors and RV function 
In a subset of experiments, healthy rat hearts were perfused with increasing concentrations of 
treprostinil (0.5-150 ng/mL) together with commercially available antagonists for the DP1  (n=8), 
EP2 (n=8) or IP receptor (n=8). The aim was to investigate the influence of each receptor subtype 
on the effect of treprostinil in the right ventricle. After stabilization, the hearts were perfused with 
the antagonist alone for 10 min, followed by increasing concentrations of treprostinil. The 
concentration of the receptor antagonist was kept constant during treprostinil perfusion. 
 
Statistics 
Unless otherwise stated, normally distributed data are presented as means±SD. Data were tested 
for normal distribution using normality test. Significance of difference was evaluated using 1-way 
ANOVA for repeated measurements followed by a relevant multiple comparisons test, 2-way 
ANOVA or Student’s t-test. Observations not normally distributed were tested with equivalent 
non-parametric tests. The p value of <0.05 was considered to represent statistical significance. All 
data were analyzed using GraphPad Prism (version 6.0, GraphPad Software, Inc., San Diego, CA). 
Results 
RV hypertrophy and failure 
Banding resulted in pressure overload to the right ventricle, demonstrated by more than a 2-fold 
increase in baseline RV developed pressure (RVDP) compared with control hearts (Figure 1A). 
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Progression of RV hypertrophy was related to the severity of PTB, shown by an increased right 
ventricle weight/tibia length in the HYP group, with an even further increase in the FAIL group 
(Figure 1B). Tricuspid annular plane systolic excursion (TAPSE) was decreased in the HYP group 
compared with the control group and in the FAIL group compared with both controls and HYP 
(CON vs. HYP, mm: 2.0±0.15 vs. 1.5±0.17, p<0.0001, CON vs. FAIL: 2.0±0.15 vs. 1.1±0.16, 
p<0.0001, HYP vs. FAIL: 1.5±0.17 vs. 1.1±0.16, p<0.0001, 1-way ANOVA) (Figure 1C).  
Cardiac output was preserved in the HYP group, contrary to the FAIL group, which had a 
significantly lower cardiac output compared with both the control group and the HYP group 
(Figure 1D). 
To assess the effect of PTB on genes related to hypertrophy and heart failure we determined the 
expression of β-MHC and SERCA-2 mRNA in the RV. Analysis revealed up-regulation of β-
MHC in the failing right ventricle and a down-regulation of SERCA-2 in the hypertrophic and 
failing right ventricle compared to controls (Figure 1E-F). Furthermore, almost half of the rats in 
the FAIL group presented with clinical manifestations of severe RV failure (Table 1). 
 
Contractile reserve of the right ventricle 
To assess the contractile reserve of the right ventricle, all hearts were perfused with dobutamine at 
the end of the protocol. Dobutamine elevated heart rate in all three groups (Figure s1A, 
supplementary material) and caused an increase in dP/dtmax (∆dP/dtmax, mmHg/sec: CON vs. 
FAIL: 2284±1225 vs. 915±823, p<0.0001, HYP vs. FAIL: 2037±1354 vs. 915±823, p<0.001, 1-
way ANOVA). Dobutamine also increased RV developed pressure (RVDP) in the controls and the 
hypertrophic hearts, but decreased RVDP in the failing hearts (∆RVDP, mmHg: CON vs. FAIL: 
26±17 vs. -17±20, p<0.0001, HYP vs. FAIL: 17±24 vs. -17±20, p<0.0001, 1-way ANOVA). 
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There was no significant difference in the increase in dP/dtmax and RVDP between controls and 
hypertrophic hearts (Figure s1B-C supplementary material). 
 
Coronary flow reserve 
When normalized to the weight of the heart, coronary flow reserve was reduced in the 
hypertrophic hearts and even lower in the failing hearts, compared to controls (CON vs. HYP: 
1.9±0.6 vs. 1.5±0.3, p<0.05, CON vs. FAIL: 1.9±0.6 vs. 1.2±0.2, p<0.0001, HYP vs. FAIL: 
1.5±0.3 vs. 1.2±0.2, p<0.01, 1-way ANOVA). There was no difference in baseline coronary flow 
between the groups when normalized to the heart weight. 
 
Effects of iloprost on RV function 
Iloprost increased coronary flow in all three groups of isolated hearts (CON: p<0.0001, HYP: 
p=0.0001, FAIL: p=0.0032, 1-way ANOVA). The increase was, however, less pronounced in the 
HYP group and even lower in the FAIL group (Figure 2A). 
Iloprost improved RV function in the control hearts, demonstrated by an increase in RVDP, 
dP/dtmax and rate pressure product (RPP) (p=0.046, p=0.035 and p=0.015, respectively, 1-way 
ANOVA). 
In the HYP group, iloprost did not alter RV function and in the FAIL group, though we observed a 
trend towards a reduction in RVDP (p=0.061, 1-way ANOVA) (Figure 2B-D). 
Iloprost did not alter heart rate in any of the groups. 
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Effects of treprostinil on RV function 
Perfusion with increasing concentrations of treprostinil increased coronary flow in the control 
hearts. The increase was lower in hearts with hypertrophic and failing right ventricle. (CON: 
p<0.0001, HYP: p=0.0008, FAIL: p=0.017, 1-way ANOVA) (Figure 3A).  
In the controls, treprostinil improved RV function, increasing RVDP, dP/dtmin and RPP (p=0.045, 
p=0.01, p=0.002, respectively, 1-way ANOVA). The effect was mainly evident for the two lowest 
concentrations, comparable to doses used in the clinic. Higher concentrations blunted the response.  
Treprostinil had a small, non-significant positive effect on RV function in the HYP group when 
administered in the lowest concentration. Increasing concentrations reduced RVDP, dP/dtmax and 
RPP below the baseline value (p=0.005, p=0.03, p=0.005, respectively, 1-way ANOVA)  
In the failing right ventricle, treprostinil impaired RV function by reducing RVDP (p=0.002, 1-
way ANOVA) (Figure 3B-D). Treprostinil elevated heart rate in the failing right ventricle 
(p=0.034, 1-way ANOVA), but heart rate was unaltered in the controls and the hypertrophic 
hearts.  
 
Effects of epoprostenol on RV function 
Epoprostenol elevated coronary flow in all hearts (CON p<0.0001, HYP p=0.0009, FAIL 
p<0.0001, 1-way ANOVA). The increase was lower in the HYP group and lowest in the FAIL 
group (Figure 4A).  
Epoprostenol improved RVDP (p=0.13) and dP/dtmax (p=0.06) in the control group (Figure 4B-
D), however it did not reach statistical significance. There was no effect of epoprostenol on the 
hypertrophic and failing hearts. 
Epoprostenol did not alter heart rate in any of the groups. 
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Effects of MRE-269 on RV function 
In controls and to a lesser extent in hypertrophic hearts, MRE-269 increased coronary flow rate. 
The increase in the FAIL group was non-significant (CON p<0.0001, HYP p=0.0009, FAIL 
p=0.074, 1-way ANOVA) (Figure 5A). 
Perfusion with MRE-269 improved RV performance in the control hearts measured by dP/dtmax, 
RPP and RVDP (p=0.003, p=0.035, p=0.085, respectively, 1-way ANOVA). In the HYP and the 
FAIL groups, MRE-269 impaired RV function markedly, when administered in supra-clinical 
concentrations (RVDP HYP: p<0.0001, RVDP FAIL: p<0.0001, 1-way ANOVA) (Figure 5B-D). 
MRE-269 did not alter heart rate in any of the groups.  
 
Coronary artery dilatation and RV function 
Treprostinil perfusion of control hearts, while keeping coronary flow constant, caused a decrease 
in RV developed pressure, dP/dtmax and RPP (p=0.006, p=0.01 and p=0.006, respectively, 1-way 
ANOVA). Perfusion with dobutamine, however, increased RVDP, dP/dtmax and RPP (Figure s2, 
supplementary material). 
Perfusion of control and hypertrophic hearts in the pressure-controlled setup with the vasodilator, 
sodium nitroprusside, increased coronary flow rate (CON p=0.001, HYP p<0.0001), RVDP (CON 
p=0.006, HYP p<0.0001) and dP/dtmax (CON p=0.024, HYP p<0.0001). In the failing hearts, 
however, the increase in coronary flow was less pronounced and there was no effect on RVDP 
(FAIL p=0.87) and dP/dtmax (FAIL p=0.56) in this group (Figure s3, supplementary material). 
 
Prostanoid receptors in the right ventricle 
Messenger RNA expression analysis revealed that all eight prostanoid receptor subtypes were 
expressed in the right ventricle from controls. In the hypertrophic right ventricle there was an 
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elevated expression of the EP1, EP3, EP4, IP and TP receptor and a reduced expression of the DP1 
receptor. In the failing right ventricle the expression of the EP2, EP3 and IP receptor was elevated, 
while the EP4 and DP1 were reduced. Expression of the EP1 and TP receptor was not significantly 
altered (Figure 6). 
Perfusion with the IP receptor antagonist, RO1138452, effectively inhibited the effect of 
treprostinil on coronary flow. It resulted in a rightward shift of the concentration-response curve 
when RO1138452 was added to the perfusion media (Figure 7A). The effect on RV function was 
also antagonized by RO1138452, causing a reduction in RVDP (Figure 7B). Perfusion with the 
DP1 receptor antagonist, BW A868C, and the EP2 receptor antagonist, PF04418948, failed to alter 
the effect of treprostinil (Figure s4, supplementary material). 
 
Discussion 
 
This study is to our knowledge the first to investigate and compare the direct effects of four 
prostacyclin mimetics on RV function in a well-established model of RV hypertrophy and failure. 
The drugs tested are used clinically for the treatment of PAH. We found that administration of 
iloprost, treprostinil and MRE-269 improved RV function in healthy control hearts. This effect, 
however, was absent in hearts with RV hypertrophy and in hearts with manifest RV failure. 
Treprostinil and MRE-269 even impaired RV function in hearts with RV failure.  
 
RV hypertrophy and failure 
With pulmonary trunk banding we created two groups of rats; one with RV hypertrophy and one 
with manifest RV hypertrophy and failure. Rats subjected to the severe banding developed RV 
hypertrophy and manifest failure, demonstrated by a major increase in RV pressures and RV 
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weight, a reduction in TAPSE and cardiac output and altered expression of genes related to 
hypertrophy and failure.23,24 These findings are comparable to both animals and humans with 
decompensated RV hypertrophy and failure5,21,25,26. Rats subjected to the mild banding presented 
with elevated RV pressures, increased RV weight, reduced TAPSE, but preserved cardiac output. 
This agrees with previous studies25,27 and suggests an adaptive remodeling of the right ventricle 
with preserved systolic function. 
Using this well-established method we were able to separate the rats into 3 distinct groups. It 
allowed us to investigate and compare the effects of prostacyclin mimetics in the healthy right 
ventricle, the hypertrophic and the failing right ventricle.  
 
Effects of iloprost, treprostinil, epoprostenol and MRE-269 on RV function 
In healthy control hearts, all four agents doubled the coronary flow. Iloprost, treprostinil and 
MRE-269 improved RV function, however only treprostinil was effective in concentrations 
comparable to those used for PAH patients. The effect of epoprostenol did not reach statistical 
significance, which agrees with previous studies, showing a tendency towards epoprostenol being 
less effective than iloprost at increasing contractility.11,28  
The differences observed among the agents may be related to their heterogeneous affinity and 
activity at the prostanoid receptors. Iloprost has a high affinity for the EP1 and IP receptor, 
whereas treprostinil has a high affinity for DP1 and EP2 receptors, though slightly less at the IP 
receptor.16,29 In this study we were able to abolish the effect of treprostinil on RV function with a 
selective IP receptor antagonist, suggesting that the IP receptor plays a role in mediating the 
function of the right ventricle. Previous studies have suggested an anti-hypertrophic effect of the 
IP receptor in the heart,30,31 which may explain the major up-regulation of this receptor in the 
hypertrophic right ventricle, but a role in RV function has to our knowledge not been demonstrated 
until now. Given the IP receptor plays a role in RV function, one might think that the selective IP 
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receptor agonist, MRE-269, would be the more potent agent. However, recent data suggest that 
MRE-269 may affect a non-typical IP receptor and/or is not completely selective to the IP receptor 
in rats.19 
 
In the hearts with hypertrophic right ventricle we found no effect of iloprost, treprostinil and 
epoprostenol, whereas MRE-269 had a small negative effect on RV function. In hearts with 
manifest RV failure the negative effect of MRE-269 was more pronounced and also treprostinil 
had a small negative effect on RV function. It suggests that the effect of the prostacyclin mimetics 
is dependent of the degree of RV hypertrophy and failure. This agrees with the study of Riise and 
collegues who reported prostanoid-mediated inotropic responses to be attenuated in the failing 
human myocardium.32 The negative effect observed in this study was however only observed with 
high supra-clinical doses. 
Reduced contractile reserve of the right ventricle may influence the effect of the prostacyclin 
mimetics in hearts with RV hypertrophy and failure. Decreased contractile reserve is associated 
with low response to pharmacological therapy in heart failure.33,34 We tested the contractile reserve 
of the right ventricle by perfusion with dobutamine. The contractile reserve of the RV was 
preserved in the hypertrophic group despite high baseline RV pressures. In the failing RV, the 
contractile reserve was on the other hand reduced. The increase in dP/dtmax was less pronounced 
and surprisingly, dobutamine decreased RVDP, indicating that the right ventricle was at the limit 
of its performance. β1 adrenoceptors have previously been shown to be down-regulated in the 
process of heart failure46 and may result in the reduced contractile reserve and response to 
dobutamine perfusion in the hearts with manifest RV failure.  
Reduced contractile reserve may partly explain the absent effect of the prostacyclin mimetics in 
the failing right ventricle. This, however, does not explain the attenuated effect in the hypertrophic 
right ventricle, where contractile reserve was preserved. The altered response in the hypertrophic 
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and failing right ventricle could be related to the altered prostanoid receptor expression. The 
prostanoid receptors cross-react at the second messenger pathway level, and a change in 
composition of the receptors in the right ventricle may alter the interaction between the receptor 
subtypes.15,29 We observed an increased expression of the EP3 receptor in the hypertrophic right 
ventricle and the receptor was even more up-regulated in the failing right ventricle. The EP3 
expression increased 3-fold compared to a 1.9-fold increase in IP receptor expression in the failing 
right ventricle. It has recently been shown that the EP3 receptor is a negative modulator of the IP 
receptor,35 and all prostacyclins will activate these receptors, with epoprostenol the most likely at 
clinical doses.13 Negative modulation of the IP receptor from the EP3 receptor may become more 
dominant in the failing right ventricle contributing to altered effect of the prostacyclin mimetics in 
the right ventricle. Indeed, EP3 receptors reduce the inotropy of beta-adrenergic stimulation in 
pigs, which may be an anti-ischemic mechanism in the heart.36  
We found an increased expression of the EP4 receptor in the HYP group, but a decreased 
expression in the FAIL group. The EP4 receptor has previously demonstrated involvement in 
cardiac hypertrophy44,45 and may explain its up-regulation in the adaptive and hypertrophic 
response in the HYP group and its down-regulation in the failing, dilating and ischaemic right 
ventricle. 
The expression of prostanoid receptors was evaluated by qPCR. A limitation of qPCR is that it 
measures messenger RNA levels, not protein levels. It will thus merely suggest changes in the 
level of protein and function than actually demonstrate it.37 The demonstration of the presence and 
level of the receptor protein was in this study limited by the lack of available specific antibodies.   
 
The prostacyclins are known for their vasodilatory effects and in this study we were also able to 
demonstrate a marked increase in coronary flow, reflecting vasodilation of the coronary arteries. 
As the increase in contractility in the control hearts was accompanied by a simultaneous increase 
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in coronary flow, we hypothesized that the mechanism of action of the prostacyclin mimetics on 
RV function, is at least partly, related to vasodilatation of the coronary arteries. To investigate this, 
we compared the effect of treprostinil on RV function under constant flow, and found that the 
positive effect of treprostinil on RV contractility was absent. This suggests that treprostinil works 
at least mainly via coronary artery dilation to increase contractility of the right ventricle rather than 
a direct inotropic effect on the cardiomyocytes. This could be explained by increased coronary 
micro-vascular filling and thus stretch of the sarcomeres and/or release of positive inotropic 
factors, leading to increased contractility.38-40 Also the nitroprusside experiments support the 
theory that coronary vasodilation could improve RV function. We found that nitroprusside, which 
can be considered a “pure” vasodilator, improved RV contractility in the control hearts and the 
hypertrophic hearts where the coronary flow was increased. This is in agreement with previous 
findings.41 In the failing hearts, where the increase in coronary flow was low, there was no effect 
on RV contractility. Further studies are, however, needed to fully confirm this mechanism. In 
contrast to the prostacyclin mimetics, dobutamine was able to increase RV contractility in the 
constant flow setup. This also indicates that the prostacyclin mimetics work through a different 
mechanism than the cardiac inotrope, dobutamine.  
 
We found no difference in baseline coronary flow among the experimental groups. The response 
to prostacyclin administration was, however, attenuated in the hypertrophic and failing hearts, 
representing a reduced coronary flow reserve at the more advanced stage of RV hypertrophy and 
failure. Coronary flow reserve has shown to be decreased in PAH patients and correlated to the 
degree of RV dysfunction.42,43 Decreased cardiomyocyte/fibrosis ratio, reduced capillary density in 
the myocardium and increased diastolic stiffness are known characteristics of our PTB model.21 
Given that the prostacyclin mimetics are dependent on increase in coronary flow to improve RV 
function, reduced coronary flow reserve, micro-vascular dysfunction, reduced capillary density 
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and increased fibrosis may contribute to the attenuated effect of the prostacyclin mimetics on RV 
function in hearts with RV hypertrophy and failure.  
 
To develop targeted treatments for patients with PAH and RV failure, it is necessary to fully 
characterize the effect of prostacyclin mimetics on RV function. The current study represents 
another step on this journey, though further studies delving deeper into the mechanism of action 
are needed.  
Limitations 
The study was carried out in rat hearts in an ex vivo experimental setup. Data from rat tissue may 
not be directly transferable to human tissue and pharmacologic effects may be different in the 
intact animal. This should be taken into consideration before clinical translation of the results. 
The banding of the rats was applied on pre-adolescent rats (approximately 90 g) to secure slow and 
gradually development of RV hypertrophy and failure. Initiation of disease development in pre-
adolescents, however, does not apply to the majority of the clinical cases of RV failure. Though it 
is unlikely to play a major role as the evaluation was performed in the fully-grown rats, this should 
be taken into consideration when interpreting the results. 
Conclusion 
Iloprost, treprostinil and MRE-269 improved RV function in the isolated healthy rat heart. The 
positive inotropic effect of these compounds was abolished in RV hypertrophy and failure, and 
MRE-269 and treprostinil even impaired the function of the right ventricle when administered in 
supra-clinical concentrations. This may be related to changes in prostanoid receptor expression 
and reduced coronary flow reserve in the hypertrophic and failing right ventricle. 
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Legends 
 
Figure 1. A-D: Influence of pulmonary trunk banding (PTB). Results are presented as means±SD. 
***p<0.001, ****P<0.0001, 1-way ANOVA. Control, n=25; Hypertrophic, n=30; Failure, n=32. 
E-F: Effect of PTB on the gene expression of SERCA-2 and β-MHC quantified by polymerase 
chain reaction, normalized to the reference gene, glyceraldehyde 3-phosphate dehydrogenase. 
Control n=8, Hypertrophic n=8, Failure n=8. Results are presented as mean±95% CI relative to 
mRNA level of controls, normalized to 1. ****p<0.0001, Student’s t-test. RV: right ventricular. 
TAPSE: Tricuspid annular plane systolic excursion. SERCA-2: sarco/endoplasmatic reticulum 
Ca2+-ATPase. B-MHC: β-Myosin heavy chain. mRNA: messenger RNA. 
 
Figure 2. Effects of iloprost on RV function in the isolated perfused heart. Control, n=7; 
Hypertrophic, n=8; Failure, n=8; Values are presented as relative to mean of baseline normalized 
to 1, +SD. †p<0.05, ††p<0.01, †††p<0.001, ††††p<0.0001, compared to baseline. *p<0.05, 
**p<0.01, ***p<0.001, ****p<0.0001, between groups. RV: right ventricular. 
 
Figure 3. Effects of treprostinil on RV function in the isolated perfused heart. Control, n=8; 
Hypertrophic, n=8; Failure, n=8. Values are presented as relative to mean of baseline normalized 
to 1, +SD. †p<0.05, ††p<0.01, †††p<0.001, compared to baseline. *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001, between groups.  RV: right ventricular. 
 
Figure 4. Effects of epoprostenol on RV function in the isolated perfused heart. Control, n=7; 
Hypertrophic, n=8; Failure, n=8. Values are presented as relative to mean of baseline normalized 
to 1, +SD. †p<0.05, ††p<0.01, †††p<0.001, compared to baseline. *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001, between groups. RV: right ventricular. 
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Figure 5. Effects of MRE-269 on RV function in the isolated perfused heart. Control, n=8; 
Hypertrophic, n=8; Failure, n=8. Values are presented as relative to mean of baseline normalized 
to 1 +SD. †p<0.05, ††p<0.01, †††p<0.001, ††††p<0.0001, compared to baseline. *p<0.05, 
**p<0.01, ***p<0.001, ****p<0.0001, between groups.  RV: right ventricular. 
 
Figure 6. Expression of mRNA for the prostanoid receptor subtypes in the RV, quantified by 
polymerase chain reaction. The data was normalized to the reference gene, glyceraldehyde 3-
phosphate dehydrogenase. Control, n=8; Hypertrophic, n=8; Failure, n=8. Results are presented as 
mean±95% CI relative to the mRNA level of the controls, normalized to 1. *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001, Student’s t-test.  RV: right ventricular. mRNA: messenger RNA. 
 
Figure 7. Effects of increasing concentrations of treprostinil (n=8) and the IP receptor antagonist, 
RO1138452 (0.5 µM), (n=8) on A: coronary flow, B: RVDP and C: heart rate. Values are 
presented as relative to mean of baseline, normalized to 1, +SD. †p<0.05, ††p<0.01, †††p<0.001, 
††††p<0.0001, compared to baseline. ***p<0.001, ****p<0.0001, between groups. RV: right 
ventricular. IPr: IP receptor. RVDP: Right ventricular developed pressure. 
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Table 1: Animal characteristics. 
 Control Hypertrophic Failure 
  Mean ± sd Mean ± sd Mean ± sd 
A)    
Body weight at termination (g) 333±10 351±21*** 312±20****†††† 
LV+S weight (g) 0.77±0.08 0.82±0.09 1.02±0.12****†††† 
Liver (g) 12.4±0.9 12.5±1.2 10.5±1.2****†††† 
Spleen (g) 0.72±0.08 0.79±0.23 0.77±0.09 
Kidney (g) 2.2±0.3 2.1±0.3 1.7±0.18****†††† 
Intraperitoneal fluid (% of group) 0 0 37.5 
Nutmeg/stase liver (% of group) 0 0 43.8 
B)    
Heart Rate (bpm) 398±23 379±22**** 333±28****†††† 
Stroke volume (uL) 264±48 301±58 199±54****†††† 
Peak velocity (mm/sec) 868±83 810±219** 466±93****†††† 
Pulsed wave tissue doppler (mm) 4.1±0.6 3.9±0.6 3.2±0.6****†††† 
Pulmonary acceleration time (ms) 29±7.3 26±13.3* 25±4.9* 
Coronary flow rate (mL/min) 10±2.4 12.7±1.7**** 16.1±2.6****†††† 
Coronary flow rate (mL/min)/heart weight (g) 11.9±2.5 10.6±1.4 10.7±2.2 
Coronary flow reserve 1.9±0.6 1.5±0.3* 1.2±0.2****†† 
 
Table 1: Animal characteristics. A) Organ weights at termination. B) Hemodynamic values at baseline. Sd: 
standard deviation. RV: right ventricle, LV+S: left ventricle+septum, * P<0.05, ** P<0.01, *** P<0.001, **** 
P<0.0001 compared to control group. †† P<0.01, †††† P<0.0001 compared to hypertrofic group. 
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Table s1. Primer sequences used for qPCR 
Gene   Primer sequence (5'→3')   
      
EP1  Forward ACTGCCACCTTCCTGTTGTT 
  Reverse GCCCAAGGCTAATGAAACAC 
      
EP2  Forward CTTGTTCCACGTGCTGGTAA 
  Reverse AAGAGCAAGGAGACCCCATA 
      
EP3  Forward TGTCAGTAGAGCAATGCAAG 
  Reverse GGATCTTTCTTAGCAGCAGA 
      
EP4  Forward AGTGACCATCGCCACATACA 
  Reverse ATGTAAGAGAAGGCGGCGTA 
      
IP  Forward GTGACCTCCATCTTCTTCTG 
  Reverse TCAGGTGGTAAACTTCATCC 
      
DP1  Forward CGGTAATAGGCTTCTCTGTGCT 
  Reverse TCCACAAGTTTAAAGGCTCCAT 
      
TP  Forward GACTGTGAGGTGGAGATGAT 
  Reverse GCGTAGGTAGATGAGCAGTT 
      
FP  Forward TCACGGGAGTCACACTTTTG 
  Reverse TGAGTTCCCAGATGTGCAAG 
      
SERCA-2a  Forward TACCAGCTGAGTCATTTCT  
  Reverse CATTGCACATCTCTATGGG  
      
β-MHC  Forward GAGCTTCTAGACATGCTGCT 
  Reverse TGGAGTTCTTCTCTTCTGGA  
      
GAPDH  Forward TTCATTGACCTCAACTACAT 
  Reverse GAGGGGCCATCCACAGTCTT 
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